Bicycle Therapeutics plc $(BCYC)$ reported its financial results for the second quarter ended June 30, 2025, with cash and cash equivalents totaling $721.5 million. The company is undergoing a strategic realignment to optimize operations, including a workforce reduction, expected to save approximately 30% in operational costs and extend its financial runway into 2028. These measures aim to focus resources on high-impact programs such as zelenectide pevedotin and the advancement of their Bicycle® Drug Conjugates and Radioconjugates. The company highlighted the ongoing Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer, which is currently open and recruiting patients. Bicycle Therapeutics also announced enhancements in its clinical leadership and the establishment of a Research and Innovation Advisory Board to support its evolving pipeline. The company remains committed to advancing its programs and delivering value-generating datasets despite uncertain market conditions.